- Sutro Biopharma expects to report interim results from a phase 1 study using STRO-002 at KOL event on Wednesday Jan. 5, 2022, at 5 p.m. ET.
- Antibody Drug Conjugate STRO-002 is being developed for the treatment of patients with ovarian cancer and endometrial cancer.
- STRO-001 is another antibody drug conjugate from Sutro's pipeline, which is being developed for the treatment of patients with B-Cell malignancies, including non-Hodgkin's lymphoma and multiple myeloma.
- There's a huge demand to use Sutro's XpressCF and XpressCF+ platforms to develop many types of therapeutics. Multiple partnerships developed proves the potential with these technologies.
For further details see:
Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching